DK2029746T3 - Sammensætninger og fremgangsmåder til siRNA-hæmning af angiogenese - Google Patents
Sammensætninger og fremgangsmåder til siRNA-hæmning af angiogeneseInfo
- Publication number
- DK2029746T3 DK2029746T3 DK07812121.7T DK07812121T DK2029746T3 DK 2029746 T3 DK2029746 T3 DK 2029746T3 DK 07812121 T DK07812121 T DK 07812121T DK 2029746 T3 DK2029746 T3 DK 2029746T3
- Authority
- DK
- Denmark
- Prior art keywords
- angiogenesis
- compositions
- methods
- sirna inhibition
- sirna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80450006P | 2006-06-12 | 2006-06-12 | |
US82497206P | 2006-09-08 | 2006-09-08 | |
US86444006P | 2006-11-06 | 2006-11-06 | |
PCT/US2007/071029 WO2007146953A2 (en) | 2006-06-12 | 2007-06-12 | Compositions and methods for sirna inhibition of angiogenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2029746T3 true DK2029746T3 (da) | 2012-10-08 |
Family
ID=38832794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07812121.7T DK2029746T3 (da) | 2006-06-12 | 2007-06-12 | Sammensætninger og fremgangsmåder til siRNA-hæmning af angiogenese |
Country Status (9)
Country | Link |
---|---|
US (1) | US20080152654A1 (da) |
EP (2) | EP2029746B1 (da) |
JP (1) | JP2009540011A (da) |
CY (1) | CY1113291T1 (da) |
DK (1) | DK2029746T3 (da) |
ES (1) | ES2390499T3 (da) |
IL (1) | IL195803A0 (da) |
PT (1) | PT2029746E (da) |
WO (1) | WO2007146953A2 (da) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050222061A1 (en) | 2002-04-18 | 2005-10-06 | Schulte Ralf W | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
EP2281885A1 (en) | 2003-08-27 | 2011-02-09 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
WO2008045576A2 (en) * | 2006-10-12 | 2008-04-17 | Yijia Liu | Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases |
US8521273B2 (en) * | 2008-01-29 | 2013-08-27 | Gilbert H. KLIMAN | Drug delivery devices, kits and methods therefor |
CA2743981C (en) | 2008-09-22 | 2019-01-29 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering rnai compounds |
NZ593743A (en) * | 2008-12-04 | 2012-07-27 | Opko Ophthalmics Llc | Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms |
US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
CA2760687A1 (en) * | 2009-05-01 | 2010-11-04 | Ophthotech Corporation | Methods for treating or preventing ophthalmological diseases |
RU2012127772A (ru) * | 2009-12-04 | 2014-01-10 | ОПКО ОФТЭЛМИКС, ЭлЭлСи | Композиции и способы для ингибирования vegf |
EP2550000A4 (en) | 2010-03-24 | 2014-03-26 | Advirna Inc | RNAI COMPOUNDS OF REDUCED SIZE ADMINISTERING |
CN106074591B (zh) | 2010-03-24 | 2020-01-14 | 菲奥医药公司 | 眼部症候中的rna干扰 |
CA2834373A1 (en) * | 2011-05-27 | 2012-12-06 | Novartis Ag | Method of treating vision disorders |
US20140227293A1 (en) | 2011-06-30 | 2014-08-14 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
US20150037422A1 (en) * | 2012-02-22 | 2015-02-05 | Trustees Of Tufts College | Compositions and methods for ocular delivery of a therapeutic agent |
TWI702955B (zh) * | 2012-05-15 | 2020-09-01 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
CA2915255A1 (en) | 2013-07-12 | 2015-01-15 | Ophthotech Corporation | Methods for treating or preventing ophthalmological conditions |
CN106414474B (zh) | 2014-03-17 | 2021-01-15 | 阿德夫拉姆生物技术股份有限公司 | 用于视锥细胞中增强的基因表达的组合物和方法 |
US11279934B2 (en) | 2014-04-28 | 2022-03-22 | Phio Pharmaceuticals Corp. | Methods for treating cancer using nucleic acids targeting MDM2 or MYCN |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
WO2016141078A1 (en) | 2015-03-02 | 2016-09-09 | Avalanche Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
SG11201805420SA (en) | 2015-12-30 | 2018-07-30 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
GB201700257D0 (en) * | 2017-01-06 | 2017-02-22 | Atlantic Pharmaceuticals (Holdings) Ltd | New formulation |
CN112111488A (zh) * | 2019-06-21 | 2020-12-22 | 苏州吉玛基因股份有限公司 | siRNA修饰物及其在抑制血管新生中的应用 |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
CN115969988A (zh) * | 2022-09-01 | 2023-04-18 | 成都景润泽基因科技有限公司 | 一种治疗新生血管性视网膜疾病的dna四面体药物复合物及其制备方法和用途 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4394448A (en) * | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4670388A (en) * | 1982-12-30 | 1987-06-02 | Carnegie Institution Of Washington | Method of incorporating DNA into genome of drosophila |
US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) * | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US5545412A (en) * | 1985-01-07 | 1996-08-13 | Syntex (U.S.A.) Inc. | N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
US5683986A (en) * | 1987-08-12 | 1997-11-04 | Hemispherx Biopharma Inc. | Elaboration of host defense mediators into biological fluids by systemic dsRNA treatment |
US5712257A (en) * | 1987-08-12 | 1998-01-27 | Hem Research, Inc. | Topically active compositions of mismatched dsRNAs |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5498521A (en) * | 1990-01-24 | 1996-03-12 | President And Fellows Of Harvard College | Diagnosis of hereditary retinal degenerative diseases |
US5843738A (en) * | 1990-08-14 | 1998-12-01 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
US5322933A (en) * | 1992-05-07 | 1994-06-21 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Crystal structure of TGF-β-2 |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
US5731294A (en) * | 1993-07-27 | 1998-03-24 | Hybridon, Inc. | Inhibition of neovasularization using VEGF-specific oligonucleotides |
US5639872A (en) * | 1993-07-27 | 1997-06-17 | Hybridon, Inc. | Human VEGF-specific oligonucleotides |
US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
US6037329A (en) * | 1994-03-15 | 2000-03-14 | Selective Genetics, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
US5505700A (en) * | 1994-06-14 | 1996-04-09 | Cordis Corporation | Electro-osmotic infusion catheter |
US5728068A (en) * | 1994-06-14 | 1998-03-17 | Cordis Corporation | Multi-purpose balloon catheter |
US6150092A (en) * | 1994-06-27 | 2000-11-21 | Taogosei Company, Ltd. | Antisense nucleic acid compound targeted to VEGF |
US5882914A (en) * | 1995-06-06 | 1999-03-16 | The Johns Hopkins University School Of Medicine | Nucleic acids encoding the hypoxia inducible factor-1 |
US20030216335A1 (en) * | 2001-11-30 | 2003-11-20 | Jennifer Lockridge | Method and reagent for the modulation of female reproductive diseases and conditions |
US5843016A (en) * | 1996-03-18 | 1998-12-01 | Physion S.R.L. | Electromotive drug administration for treatment of acute urinary outflow obstruction |
US7033598B2 (en) * | 1996-11-19 | 2006-04-25 | Intrabrain International N.V. | Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal |
US6165709A (en) * | 1997-02-28 | 2000-12-26 | Fred Hutchinson Cancer Research Center | Methods for drug target screening |
JP3726857B2 (ja) * | 1997-05-02 | 2005-12-14 | ソニー株式会社 | 受信装置および受信方法 |
US5902598A (en) * | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
EP0979869A1 (en) * | 1998-08-07 | 2000-02-16 | Hoechst Marion Roussel Deutschland GmbH | Short oligonucleotides for the inhibition of VEGF expression |
US6219557B1 (en) * | 1998-12-11 | 2001-04-17 | Ericsson Inc. | System and method for providing location services in parallel to existing services in general packet radio services architecture |
ATE276199T1 (de) | 1999-02-03 | 2004-10-15 | Biosante Pharmaceuticals Inc | Methoden zur herstellung von therapeutische kalzium-phosphat partikeln |
US6121000A (en) * | 1999-02-11 | 2000-09-19 | Genesense Technologies, Inc. | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase |
US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
CA2403397A1 (en) * | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Methods and compositions for rna interference |
AU2001249622B2 (en) * | 2000-03-30 | 2007-06-07 | Massachusetts Institute Of Technology | RNA sequence-specific mediators of RNA interference |
US6372250B1 (en) * | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
US6375972B1 (en) | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
US6852510B2 (en) * | 2000-07-03 | 2005-02-08 | Gala Design Inc | Host cells containing multiple integrating vectors |
US6443145B1 (en) * | 2000-08-25 | 2002-09-03 | Learning Legacy | Solar seeker |
US20020132788A1 (en) * | 2000-11-06 | 2002-09-19 | David Lewis | Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo |
US20020173478A1 (en) * | 2000-11-14 | 2002-11-21 | The Trustees Of The University Of Pennsylvania | Post-transcriptional gene silencing by RNAi in mammalian cells |
KR100909681B1 (ko) * | 2000-12-01 | 2009-07-29 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | Rna 간섭을 매개하는 작은 rna 분자 |
US20020165158A1 (en) * | 2001-03-27 | 2002-11-07 | King George L. | Methods of modulating angiogenesis |
JP2002305193A (ja) * | 2001-04-05 | 2002-10-18 | Sony Corp | 半導体装置とその製造方法 |
US20050187174A1 (en) * | 2001-05-18 | 2005-08-25 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) |
US20050048529A1 (en) * | 2002-02-20 | 2005-03-03 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) |
US20050159380A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA) |
US7517864B2 (en) * | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050148530A1 (en) * | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
ES2546829T3 (es) * | 2001-07-23 | 2015-09-29 | The Board Of Trustees Of The Leland Stanford Junior University | Métodos y composiciones para la inhibición mediada por iARN de la expresión génica en mamíferos |
WO2003040399A2 (en) * | 2001-11-02 | 2003-05-15 | Intradigm Corporation | Therapeutic methods for nucleic acid delivery vehicles |
WO2003046173A1 (fr) * | 2001-11-28 | 2003-06-05 | Center For Advanced Science And Technology Incubation, Ltd. | Systeme d'expression d'arn si et procede de production de cellules d'inactivation de genes fonctionnelles et analogues au moyen de ce systeme |
EP1501930A2 (en) * | 2002-04-05 | 2005-02-02 | Santaris Pharma A/S | Oligomeric compounds for the modulation hif-1alpha expression |
US20050222061A1 (en) * | 2002-04-18 | 2005-10-06 | Schulte Ralf W | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
US20040115640A1 (en) * | 2002-12-11 | 2004-06-17 | Isis Pharmaceuticals Inc. | Modulation of angiopoietin-2 expression |
US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
CA2504926C (en) * | 2002-11-01 | 2014-01-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for sirna inhibition of hif-1 alpha |
EP1560931B1 (en) * | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
EP2251434B1 (en) * | 2003-01-16 | 2014-07-30 | The Trustees of The University of Pennsylvania | Compositions and methods for siRNA inhibition of ICAM-1 |
WO2004094606A2 (en) * | 2003-04-18 | 2004-11-04 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOPOIETIN 1 AND 2 AND THEIR RECEPTOR TIE2 |
US20050019927A1 (en) * | 2003-07-13 | 2005-01-27 | Markus Hildinger | DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER |
US7947659B2 (en) * | 2004-03-12 | 2011-05-24 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeting VEGF |
US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
ATE466081T1 (de) * | 2005-12-22 | 2010-05-15 | Opko Ophthalmics Llc | Zusammensetzungen und verfahren zur regulierung eines komplementsystems |
EP1982176A1 (en) * | 2006-01-30 | 2008-10-22 | Dako Denmark A/S | High-speed quantification of antigen specific t-cells in whole blood by flow cytometry |
-
2007
- 2007-06-12 ES ES07812121T patent/ES2390499T3/es active Active
- 2007-06-12 US US11/761,940 patent/US20080152654A1/en not_active Abandoned
- 2007-06-12 DK DK07812121.7T patent/DK2029746T3/da active
- 2007-06-12 PT PT07812121T patent/PT2029746E/pt unknown
- 2007-06-12 EP EP07812121A patent/EP2029746B1/en active Active
- 2007-06-12 EP EP11171243A patent/EP2383341A1/en not_active Ceased
- 2007-06-12 JP JP2009515610A patent/JP2009540011A/ja active Pending
- 2007-06-12 WO PCT/US2007/071029 patent/WO2007146953A2/en active Application Filing
-
2008
- 2008-12-08 IL IL195803A patent/IL195803A0/en unknown
-
2012
- 2012-10-02 CY CY20121100913T patent/CY1113291T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2007146953A8 (en) | 2009-11-19 |
WO2007146953A2 (en) | 2007-12-21 |
EP2029746B1 (en) | 2012-07-04 |
IL195803A0 (en) | 2011-08-01 |
CY1113291T1 (el) | 2016-04-13 |
JP2009540011A (ja) | 2009-11-19 |
EP2029746A2 (en) | 2009-03-04 |
ES2390499T3 (es) | 2012-11-13 |
EP2383341A1 (en) | 2011-11-02 |
US20080152654A1 (en) | 2008-06-26 |
PT2029746E (pt) | 2012-10-15 |
WO2007146953A3 (en) | 2008-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2029746T3 (da) | Sammensætninger og fremgangsmåder til siRNA-hæmning af angiogenese | |
DK2274008T3 (da) | Sammensætninger og fremgangsmåder til hæmning af PDGFRBETA og VEGF-A | |
DK2470656T3 (da) | Sammensætning til hæmning af genekspression og anvendelser heraf | |
DK2271642T3 (da) | Pyridylinhibitorer af hedgehog signalering | |
DK3272879T3 (da) | Transposonendesammensætninger og fremgangsmåder til modificering af nukleinsyrer | |
DK2001611T3 (da) | Fremgangsmåde og sammensætning til oprensning af jord | |
DK2097402T3 (da) | Makrocykliske inhibitorer af hepatitis c-virus | |
DK2170403T3 (da) | Sammensætninger og fremgangsmåder til hæmning af ekspressionen af proapoptotiske gener | |
DK2120579T3 (da) | Inhibitorer af poly(ADP-ripose)polymerase | |
DK2203478T3 (da) | Sammensætninger og fremgangsmåder til anvendelse af antistoffer mod sclerostin | |
DK2081669T3 (da) | Fremgangsmåde og anordning til fremstilling af granulater | |
DK3208269T3 (da) | Inhibitorer af c-fms-kinase | |
DK3795573T3 (da) | Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf | |
DK2212070T3 (da) | Fremgangsmåde til behandling af træ | |
DK2323638T3 (da) | Sammensætninger og fremgangsmåder til behandling af osteoartritis | |
DK2032156T3 (da) | Sammensætninger og fremgangsmåder til levering af oxygen | |
DK2086960T3 (da) | Nye inhibitorer af glutaminylcyclase. | |
DK2015754T3 (da) | Anvendelse af dpp-iv-inhibitorer | |
DK2478907T3 (da) | Sammensætninger til behandling af kræft | |
DK2155188T3 (da) | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft | |
DK2091945T3 (da) | Nye inhibitorer af glutaminylcyclase | |
DK3192500T3 (da) | Sammensætninger til kontinuerlig indgivelse af dopa-decarboxylasehæmmere | |
DK2565193T3 (da) | Sammensætninger og fremgangsmåder til hæmning af JAK-signalvejen | |
DK3081215T3 (da) | Sammensætninger og fremgangsmåder til langvarig frigørelse af beta-alanin | |
DK2700786T3 (da) | Modifikation af overførselspassage |